Navigation Links
Solta Medical Announces FDA 510(k) Clearance of Fraxel re:store Dual Laser System for the Treatment of Actinic Keratosis
Date:9/16/2010

HAYWARD, Calif., Sept. 16 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced it has received FDA 510(k) clearance of its Fraxel re:store®Dual for the treatment of actinic keratosis (AKs). The Fraxel re:store Dual system takes the industry leading fractional laser technology to the next level by adding a novel 1927 nm wavelength, the first ever application of a Thulium laser in the aesthetics market.  The Fraxel re:store Dual treatment provides superior results for the removal of AKs – a common precancerous skin condition caused by sun exposure on the face or other areas of the body.

During a six month clinical study of 21 subjects at several dermatology centers around the country, there was an 83.5% average reduction of AK lesions using the Fraxel re:store Dual's 1927 nm wavelength. Treatments were shown to be effective both on and off the face, including the arms, hands and chest area.  Each subject underwent a series of two to four treatments with the Fraxel re:store Dual that were spaced two to four weeks apart. No adverse reactions occurred for any of the subjects. In addition, the study found improvement in skin texture and pigmentation following a Fraxel treatment.  

"In our study, we found the Fraxel re:store Dual to be the most effective treatment of multiple facial AKs, as it is safe and requires minimal downtime while simultaneously improving other signs of photodamage," said Roy G. Geronemus, MD, Director of the Laser & Skin Surgery Center of New York. "While the 83.5% removal rate was comparable to other topical therapies and AK treatment options, Fraxel was overwhelmingly well-tolerated by all the patients and offers the added benefit of improving a patients' overall skin quality, color and texture."

"By using the Fraxel Dual's 1927 nm wavelength, we were able to see dramatic clinical clearing of facial AKs in our patients after a series of treatments," said Suzanne L. Kilmer, MD, Founder of the Laser & Skin Surgery Center of Northern California. "My patients will now have an effective and safe treatment option for the removal of precancerous lesions on their face as well as on the body."  

"Solta Medical continues to develop safe, innovative anti-aging solutions that deliver the best possible results in non-invasive aesthetic treatments," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc.  "With the FDA clearance of our Fraxel re:store Dual system, we are providing our physicians with cutting-edge technology that patients are seeking, specifically in terms of reversing sun damage and treating precancerous skin lesions."  

ABOUT SOLTA MEDICAL, INC.

Solta Medical is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's three premier brands: Thermage®, Fraxel® and Isolaz®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.solta.com.

© 2010 Solta Medical, Inc. All rights reserved. Thermage, Fraxel, Fraxel re:store, Isolaz and Solta Medical are trademarks or registered trademarks of Solta Medical, Inc. or its subsidiaries.


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System
2. Solta Medical Donates Fraxel re:store(R) Laser System to Grossman Burn Foundation
3. Solta Medical Announces New Fraxel re:store(R) Dual Laser System, Receives CE Mark for European Market
4. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
5. Solta Medical to Participate in 2nd Annual Lazard Capital Markets Medical Technology Conference
6. Solta Medical and Alma Lasers Resolve Patent Lawsuits
7. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
8. Solta Medical Announces Thermage CPT™ and Fraxel re:store® Dual Systems Receive Health Canada Approval
9. Solta Medical, Inc. Announces Second Quarter 2010 Results Release Date and Conference Call
10. Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a ... he has leant his presence to an educational purpose as the host of the ... one being cancer. In a recent episode, the series focuses on thyroid cancer. , ...
Breaking Medicine News(10 mins):